FDA
-
-
-
-
-
-
-
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
-
-
-
-
-
-
-
AxoGen, Inc. (AXGN) PT Raised to $28 at Leerink Partners
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on AxoGen, Inc. (AXGN)
-
-
-
-
-
-
-
AxoGen (AXGN) Completes Submission of BLA to U.S. Food and Drug Administration for Avance Nerve Graft®
-
-
-
-
-
-
-
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
-
-
-
-
-
-
-
AxoGen (AXGN) Reports Positive Topline Results from Phase 3 RECON(SM) Study
-
-
-
-
-
-
-
Axogen, Inc. Reports 2021 Second Quarter Financial Results
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

